Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
SB 525334
Cat. No.:
OB0225LY-0186
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Add to basket
Product Overview
Description:
SB 525334 is a selective inhibitor that specifically targets the TGF-β signaling pathway involved in the regulation of cell proliferation and fibrosis processes.
Synonym:
SB525334; 356559-20-1; 6-(2-(tert-Butyl)-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline; 6-(2-(1,1-Dimethylethyl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl)-quinoxaline; Quinoxaline, 6-(2-(1,1-dimethylethyl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl)-
CAS No.:
356559-20-1
Compound CID:
9967941
Formula:
C21H21N5
Formula Weight:
343.42
Specification
Relative Density:
1.191 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
SB 525334 can be used in fibrosis research or play an important role in immunomodulation.
Library Information
Targets:
TGF-beta/Smad; ALK family
Receptors:
ALK4; ALK5; TGF-β receptor; TβR1I
Pathways:
Angiogenesis; Stem cells; Tyrosine kinase/adaptors
Plate Number:
AOCL-3
Plate Location:
c10
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Special Max Solubility:
1eq. HCl: 34.3 mg/mL
ALogP:
4.305
HBA_Count:
4
HBD_Count:
1
Rotatable Bond:
3
